SPARTHA MEDICAL
Description
SPARTHA Medical is a French Biotech company issued from the French National Institute of Health Research that develops multifunctional formulations (antibacterial, antifungal, antiviral, and pro-regenerative). These formulations are first targeted for hospital-acquired infections which are one of the main burdens on health insurance.
Currently, we are raising 5.1 M€ for the clinical trials and CE marking of our first product protect|ION, which is a handheld supramolecular coating spraying system that can apply our protective membranes to open wounds during surgeries. This can significantly decrease hospitalisation time and medical expenses. We have 3.1 M€ committed already. This clinical trial will enable us to obtain the CE mark and expand our commercial activity and get into the growth phase.
Our formulations can also be applied to existing products; we provide this as a service and have already been commercially active with this service activity (www.sparthashield.com) Revenues since 2022) with the end-point of out-licensing our technology for a specific application (one out-licensing deal signed with a German Multinational already).
We have 4 other ongoing projects for different applications with multinationals. In the long run, we aim to develop them as antibiotic alternatives.
Company members
21 employee
